uniQure Announces Plan for BLA Submission of Huntington’s Disease Gene Therapy AMT-130, FDA Accepts Phase 1/2 3-Year Data for Accelerated Approval

uniQure Press Release USA

Overview

uniQure has announced that the FDA agreed in a Type B meeting that 3-year analysis data from its Phase 1/2 trial of gene therapy AMT-130 for Huntington’s Disease (HD) would be acceptable as primary evidence for an Accelerated Approval pathway. AMT-130 already holds RMAT, Breakthrough Therapy, and Fast Track designations from the FDA. This pivotal development significantly expedites the potential market entry of the first disease-modifying gene therapy for a devastating neurodegenerative condition.

In Depth

Key Findings

uniQure has announced a significant step forward in its regulatory strategy for AMT-130, its gene therapy candidate for Huntington’s Disease (HD). Following a Type B meeting with the U.S. Food and Drug Administration (FDA), uniQure confirmed that the FDA agreed to accept 3-year analysis data from its ongoing Phase 1/2 clinical trial as the primary basis for a Biologics License Application (BLA) submission via the Accelerated Approval pathway. This decision marks a critical milestone that could significantly accelerate the availability of the first potential disease-modifying treatment for this fatal neurodegenerative disorder.

Technical & Clinical Details

• AMT-130’s Mechanism: AMT-130 is an adeno-associated virus (AAV) serotype 5-based gene therapy designed for one-time intracerebral administration. It delivers a microRNA that silences the expression of the Huntingtin (HTT) gene, aiming to reduce the production of both mutant and wild-type HTT protein, which is central to the pathophysiology of HD. This approach seeks to slow or halt the progression of the disease by addressing its genetic root cause.
• Clinical Data Acceptance: The FDA’s acceptance of the 3-year Phase 1/2 data for Accelerated Approval indicates that the observed clinical effects and biomarker changes are considered sufficiently robust and clinically meaningful to warrant an expedited review. While specific efficacy metrics (e.g., changes in UHDRS scores or neurofilament light chain (NfL) levels) are anticipated in future detailed presentations, this regulatory green light underscores the promising profile of AMT-130.
• Regulatory Designations: AMT-130 has previously received multiple key designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy Designation (BTD), and Fast Track designation. These designations are intended to facilitate the development and expedite the review of drugs for serious conditions that address unmet medical needs.

Background & Context

Huntington’s Disease is a devastating, inherited neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric symptoms, ultimately leading to death. Currently, there are no approved therapies that can slow or stop the progression of HD; treatments are primarily symptomatic. The potential for a gene therapy like AMT-130 to offer a disease-modifying effect represents a monumental advance for patients and their families. The FDA’s willingness to consider early-phase data for accelerated approval highlights the significant unmet need in HD and a flexible regulatory approach to highly innovative genetic medicines.

Strategic Significance & Outlook

uniQure is now poised to accelerate its BLA submission efforts based on this FDA feedback. While the Accelerated Approval pathway offers a quicker route to market, it typically requires post-marketing confirmatory studies to verify clinical benefit. If approved, AMT-130 would be the first gene therapy for HD and a significant landmark for the broader gene therapy field. Investors and the patient community will closely monitor the precise timeline for BLA submission and the subsequent regulatory review process, anticipating a new era in the management of this challenging disease.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime